This website uses cookies

We use cookies and website tracking tools to provide you with the best online experience. Learn more in our /en/news/hih-news/privacy-notice/privacy statement.

if you accept, your choice will be valid until cancellation.

If you disallow cookies, functionality of our website might be limited.

 

Merk Lab

Experimental Pediatric Neuro-Oncology

Brain tumors are the leading cause of cancer-related deaths in infants, children, and adolescents. Our lab is mostly focusing on embryonal brain tumors including medulloblastoma, atypical teratoid rhabdoid tumors (ATRTs), and embryonal tumors with multilayered rosettes (ETMRs). Due to the lack of targeted therapies for these tumors, survival rates remain poor.

The primary aim of the lab is to identify novel targeted therapies for children with brain tumors that will result in improved survival rates and fewer long-term side effects. We are currently employing genome-wide CRISPR/Cas9 knockout screens in order to develop comprehensive maps of genetic dependencies for distinct forms of embryonal brain tumors. We correlate these essentialities with molecular features such as genetic alterations and global gene expression profiling in order to gain further insights into the molecular biology of these devastating tumors. Furthermore, we validate the most promising candidates in in vitro drug screens and in vivo mouse models to further evaluate their potential for clinical translation.

Resistance to anti-cancer treatments is a major obstacle to a cure for many brain tumor patients. We are therefore also interested in tumor-drug interactions, and how those relate to novel combination therapies and potential resistance mechanisms that will allow cancer cells to overcome targeted therapies.

Publications
Members
Outpatient clinic

Selected publications

 

Niessner H, Schmitz J, Tabatabai G, Schmid A, Calaminus C, Sinnberg T, Weide B, Eigentler TK, Garbe C, Schittek B, Quintanilla-Fend L, Bender B, Mai M, Praetorius C, Beissert S, Schackert G, Muders M, Meinhardt M, Baretton GB, Dummer R, Flaherty KT, Pichler BJ, Kulms D, Westphal D, Meier F. PI3K pathway inhibition achieves potent antitumor activity in melanoma brain metastases in vitro and in vivo. Clin Cancer Res. 2016. [Epub ahead of print]

 

Skardelly M, Brendle E, Noell S, Behling F, Wuttke TV, Schittenhelm J, Bisdas S, Meisner C, Rona S, Tatagiba MS, Tabatabai G. Predictors of preoperative and early postoperative seizures in patients with intra-axial primary and metastatic brain tumors: A retrospective observational single center study. Ann Neurol. 2015;78(6):917-28.

 

Weller M, Tabatabai G, Kästner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bähr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkhah G, Meixensberger J, Vajkoczy P, Kollias S, Hüsing J, Reifenberger G, Wick W; DIRECTOR Study Group. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Clin Cancer Res. 2015 May 1;21(9):2057-64. doi: 10.1158/1078-0432.CCR-14-2737. Epub 2015 Feb 5.

 

Wirsching HG, Krishnan S, Florea AM, Frei K, Hasenbach K, Reifenberger G, Krayenbuehl N, Weller M, Tabatabai G. Thymosin β4 gene silencing decreases stemness and invasiveness in glioblastoma. Brain 2014;137:433-48 

 

Gulbins E, Palmada M, Reichl M, Lüth A, Böhmer C, Amato D, Müller CP, Tischbirek CH, Groemer TW, Tabatabai G, Becker KA, Tripal B, Staedtler S, Ackerman TF, van Brederode J, Alzheimer C, Weller M, Lang UE, Kleuser B, Grassme H, Kornhuber J. Acid sphingomyelinase-ceramide system mediates effects of antidepressant drugs. Nat Med 2013;19:934-938 

 

Gramatzki D, Herrmann C, Happold C, Becker KA, Gulbins E, Weller M, Tabatabai G. Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway. PLoS One 2013; 7;8(5):e63527

 

Spescha RD, Shi Y, Wegener S, Keller S, Weber B, Wyss MM, Lauinger N, Tabatabai G, Paneni F, Consentino F, Hock C, Weller M, Nitsch RM, Lüscher TF, Camici GG. Deletion of the ageing gene p66Shc reduces early stroke size following ischaemia/reperfusion brain injury. Eur Heart J. 2013; 34: 96-103 

 

Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomized, phase 3 trial. Lancet Oncol 2012; 13:707-715 

 

Hasenbach K, Wiehr S, Herrmann C, Mannheim J, Cay F, von Kürthy G, Bolmont T, Grathwohl SA, Weller M, Lengerke C, Pichler B, Tabatabai G. Monitoring the glioma tropism of bone marrow-derived progenitor cells by two-photon laser scanning microscopy and positron emission tomography. Neuro Oncol 2012; 12:302-307 

 

Schraivogel D, Weinmann L, Beier D, Tabatabai G, Eichner A, Zhu JY, Anton M, Sixt M, Weller M, Beier CP, Meister G. CAMTA is a novel tumor suppressor regulated by miR-9/9* in glioblastoma cells. EMBO J 2011; 30, 4309-4322


 
Name
Research Group
Phone
Email
Dr. Daniel Merk
Dr. Daniel Merk
Pediatric Neurooncology

+49 (0)7071-
29-81960

 
 Foteini Tsiami
Foteini TsiamiPhD Student
Pediatric Neurooncology

+49 (0)7071-
29-82043

 

 

 

Neuro-Oncological Outpatient Clinic

 

The neurological and neurosurgical Neuro-Oncological Outpatient Clinic have been united by the Interdisciplinary Division Neuro-Oncology under the roof of the Centre for Neuro-Oncology at the Southwest German Cancer Centre. The range of service of the Outpatient Clinic includes the pre-and post-operative consultations, care and treatment of the patients with neuro-oncological tumors.

 

 

 

 

 

 

 

 

 

Consultation hours, contact persons and further information can be found on the page of the Neuro-Oncological Outpatient Clinic of the University Hospital Tübingen.

Junior Research group leader
Dr. Daniel MerkPhone Phone +49 (0)7071 29-81960daniel.merk@uni-tuebingen.deAddress

Center of Neurology
Hertie Institute for Clinical Brain Research
Department Neurology and Interdisciplinary Neuro-Oncology

Otfried-Müller-Straße 27
72076 Tübingen